Heron Therapeutics, Inc. (HRTX) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated February 26, 2026, reports the issuance of an earnings press release by Heron Therapeutics, Inc. The filing covers financial results for the three and twelve months ended December 31, 2025. The company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol HRTX.
Key Financial Metrics
The provided filing text serves as a cover document referencing an attached press release (Exhibit 99.1) but does not contain specific numerical data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the reported period.
Material Changes
No material changes versus prior periods are detailed within the text of this Form 8-K. The document solely announces the availability of the results for the three and twelve months ended December 31, 2025.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" under Section 18 of the Exchange Act. It is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated. No specific guidance, management commentary, risks, or contingencies are described in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 26, 2026) for actual financial figures.
- Verify the specific revenue and net loss figures for the three and twelve months ended December 31, 2025.
- Check the cash balance and burn rate disclosed in the full press release.
- Confirm any updates to clinical trial milestones or pipeline developments mentioned in the attached exhibit.